A Phase 3 interventional study of DR-1011 in Contraception, sponsored by Duramed Research. Completed at 55 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-16.
Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.
Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.
First submitted before Duramed Research became part of Teva Pharmaceutical Industries, Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.
Drug: DR-1011
Drug pages: Levonorgestrel · Ethinyl Estradiol
Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
Also known as: levonorgestrel/ethinyl estradiol
Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy
Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)
Time frame: up to one year
Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy
Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)
Time frame: up to one year
Participants With Treatment-Emergent Adverse Events
Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values.
Time frame: Day 1 up to one year
| Milestone | DR-1011 |
|---|---|
| Started | 2235 |
| Safety population | 2185 |
| Pregnancy intent-to-treat cohort (pitt) | 1735 |
| Completed | 1249 |
| Not completed | 986 |
| Withdrew: Did not meet protocol requirements | 64 |
| Withdrew: Non-compliance with the protocol | 81 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 225 |
| Withdrew: Adverse event | 253 |
| Withdrew: Pregnancy | 34 |
| Withdrew: Lost to follow-up | 304 |
| Withdrew: Other | 22 |
Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)
| pregnancies per 100 woman years exposure | DR-1011 |
|---|---|
| Excluding other BCMs (n=1732) | 2.44 |
| All complete cycles (n=1735) | 2.42 |
| Compliant-Use (n=1685) | 1.77 |
Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values.
| participants | DR-1011 |
|---|---|
| Participants With Treatment-Emergent Adverse Events | 1742 |
Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)
| pregnancies per 100 woman years exposure | DR-1011 |
|---|---|
| Excluding other BCMs (n=1732) | 2.15 |
| All complete cycles (n=1735) | 2.12 |
| Compliant-Use (n=1685) | 1.77 |
Collected over Day 1 up to one year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DR-1011 | — | 34/2,185 (1.6%) | 1,333/2,185 (61%) |
| Event | DR-1011 |
|---|---|
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 4/2185 |
| APPENDICITISInfections and infestations | 2/2185 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 2/2185 |
| CHOLELITHIASISHepatobiliary disorders | 2/2185 |
| ABDOMINAL PAIN UPPERGeneral disorders | 1/2185 |
| ABORTION MISSEDPregnancy, puerperium and perinatal conditions | 1/2185 |
| BILIARY DILATATIONHepatobiliary disorders | 1/2185 |
| BILIARY DYSKINESIAHepatobiliary disorders | 1/2185 |
| CERVICOBRACHIAL SYNDROMENervous system disorders | 1/2185 |
| CHOLECYSTITISHepatobiliary disorders | 1/2185 |
| Event | DR-1011 |
|---|---|
| HEADACHENervous system disorders | 732/2185 |
| NASOPHARYNGITISInfections and infestations | 362/2185 |
| DYSMENORRHOEAReproductive system and breast disorders | 250/2185 |
| NAUSEAGastrointestinal disorders | 190/2185 |
| METRORRHAGIAReproductive system and breast disorders | 183/2185 |
| BACK PAINMusculoskeletal and connective tissue disorders | 175/2185 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 174/2185 |
| SINUSITISInfections and infestations | 157/2185 |
| URINARY TRACT INFECTIONInfections and infestations | 118/2185 |
Safety population
| Age, Continuous(years) | DR-1011 |
|---|---|
| Mean | 27.7 ± 5.80 |
| Sex: Female, Male(Participants) | DR-1011 |
|---|---|
| Female | 2185 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | DR-1011 |
|---|---|
| African-American | 256 |
| Asian | 36 |
| Caucasian | 1627 |
| Hispanic | 218 |
| Other | 48 |
| Region of Enrollment(participants) | DR-1011 |
|---|---|
| United States | 2185 |
| Weight(pounds) | DR-1011 |
|---|---|
| Mean | 158.7 ± 41.26 |
| Body Mass Index(kg/m^2) | DR-1011 |
|---|---|
| Mean | 26.7 ± 6.65 |
The record gives a start of Jun 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol